Following antibiotic treatment for Lyme disease, some patients report persistent or relapsing symptoms of pain, fatigue, and/or cognitive deficits. Factors other than active infection, including immune abnormalities, have been suggested, but few clues regarding mechanism have emerged. Furthermore, the effect of antibiotic treatment on immune response in affected individuals remains unknown. In this study, a longitudinal analysis of specific immune markers of interest was carried out in patients with a history of Lyme disease and persistent objective memory impairment, prior to and following treatment with either ceftriaxone or placebo. IFNα activity was measured by detection of serum-induced changes in specific target genes, using a functional cell-based assay and quantitative real-time PCR. Level and pattern of antibody reactivity to brain antigens and to Borrelia burgdorferi proteins were analyzed by ELISA and immunoblotting. Sera from the patient cohort induced significantly higher expression of IFIT1 and IFI44 target genes than those from healthy controls, indicating increased IFNα activity. Antibody reactivity to specific brain and borrelial proteins was significantly elevated in affected patients. IFNα activity and antibody profile did not change significantly in response to ceftriaxone. The heightened antibody response implies enhanced immune stimulation, possibly due to prolonged exposure to the organism prior to the initial diagnosis and antibiotic treatment of Lyme disease. The increase in IFNα activity is suggestive of a mechanism contributing to the ongoing neuropsychiatric symptoms.
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Introduction
Lyme borreliosis is a multisystem infection that is caused by spirochetes of the Borrelia burgdorferi sensu lato genospecies complex and transmitted by Ixodes ticks (Stanek and Strle, 2003) . It is endemic to North America, Europe, and Asia (Steere, 2001; Stanek and Strle, 2008) . The early phase of the infection is usually associated with a characteristic skin lesion, known as erythema migrans (EM) (Bratton et al., 2008) . Extracutaneous manifestations of Lyme disease may affect the joints, heart, and/or the nervous system (Steere, 2001; Wormser et al., 2006) . Neurologic complications include lymphocytic meningitis, cranial neuropathy, peripheral neuropathy, and encephalopathy characterized by deficits in cognitive functioning (Halperin, 2008) . Although these complications typically respond well to currently standard antibiotic therapy, some Lyme disease patients report persistent symptoms despite treatment (Feder et al., 2007; Marques, 2008) . The symptoms in affected patients include musculoskeletal pain, fatigue, and difficulties with verbal fluency and memory (Feder et al., 2007; Marques, 2008) . The condition has been variably referred to as chronic Lyme disease, post-treatment Lyme disease syndrome, and post-Lyme disease syndrome (PLDS).
Despite several years of debate, few clues to the causes of the persistent symptoms following the treatment of Lyme disease have emerged and the search for effective therapeutic options has remained elusive. In addition, there is no definitive test or biomarker to link the presence of persistent symptoms in the affected patients to having been infected with B. burgdorferi in the past. A recent study demonstrated heightened levels of antibodies to brain proteins in patients with PLDS, thus for the first time demonstrating the presence of certain objective immunologic abnormalities that may be relevant to the pathogenic mechanism of the symptoms experienced (Chandra et al., 2010) . Another study on the same patients showed increased antibody reactivity towards specific B. burgdorferi proteins in comparison to post-Lyme healthy individuals (Chandra et al., 2011b) . Furthermore, epitope mapping of the immune response to VlsE protein of B. burgdorferi in these patients revealed elevated antibody reactivity to specific sequences in the membrane-proximal region of the protein (Chandra et al., 2011a) . These findings have offered useful
